Is Regeneron Stock a Buy After a Regulatory Blow?
Biotech giant Regeneron (NASDAQ: REGN) has been an outstanding performer over the past year. And although its stock is still up by 20% in the trailing-12-month period, the company's shares recently took a significant blow, dropping by 8% in one day. For a company the size of Regeneron -- with a market capitalization of $78.7 billion -- that's a massive one-day dip.
Regeneron suffered this blow following a regulatory obstacle, as is often the case in the biotech industry (more on that below). Do these developments represent an excellent opportunity to buy Regeneron's shares on the dip? Or should investors stay away from the company? Let's find out.
Source Fool.com
Regeneron Pharmaceuticals Inc. Aktie
995,60 €
1,78 %
Starke Kaufneigung bei Regeneron Pharmaceuticals Inc., mit mehr Buy- als Sell-Einschätzungen.
Ein positives, wenn auch bescheidenes, Potenzial für Regeneron Pharmaceuticals Inc. mit einem Kursziel von 1064 € im Vergleich zum aktuellen Kurs von 995.6 €.
